(Q38062462)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

HIV Drug Resistance and the Advent of Integrase Inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

3

Mark A Wainberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1

Peter K Quashie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

1 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

Current infectious disease reports

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

85-100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180144%20AND%20SRC:MED&resulttype=core&format=json

Integrase and integration: biochemical activities of HIV-1 integrase

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Structural biology of retroviral DNA integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

The structural biology of HIV-1: mechanistic and therapeutic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Integrase inhibitors: a novel class of antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Raltegravir and etravirine are active against HIV type 1 group O.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Elvitegravir: a once-daily inhibitor of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Dolutegravir for the treatment of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

The mechanism of retroviral integration from X-ray structures of its key intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

HIV-1 IN strand transfer chelating inhibitors: a focus on metal binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Identification of critical motifs within HIV-1 integrase required for importin α3 interaction and viral cDNA nuclear import.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Drug-target residence time and its implications for lead optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Isolation of drug-resistant mutant HIV variants using tissue culture drug selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Resistance to HIV-1 integrase inhibitors: A structural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Design and development of integrase inhibitors as anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Rational drug design of DNA oligonucleotides as HIV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Emerging pharmacology: inhibitors of human immunodeficiency virus integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Structural determinants for HIV-1 integrase inhibition by beta-diketo acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Raltegravir: is a 400 mg once-daily dose enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

[Resistance to integrase inhibitors].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

HIV-1 integrase inhibitor resistance and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Integrase inhibitors effective against human T-cell leukemia virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

21 January 2018

Integrase illuminated

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Retroviral intasome assembly and inhibition of DNA strand transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Structure-based modeling of the functional HIV-1 intasome and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Structural insights into the retroviral DNA integration apparatus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

A structure-information approach to the prediction of biological activities and properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Computer tools in the discovery of HIV-1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

MK-0536 inhibits HIV-1 integrases resistant to raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, Dihydroxypyrimidines, and bicyclic pyrimidinones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Simplified molecular input-line entry system and International Chemical Identifier in the QSAR analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Cellular co-factors of HIV-1 integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

The role of unintegrated DNA in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

GCN5-dependent acetylation of HIV-1 integrase enhances viral integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: a promising approach in anti-retroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Rationale and uses of a public HIV drug-resistance database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0305-1

Evolutionary mechanisms of retroviral persistence.

21 January 2018

1 reference

12 December 2020

Single-tablet Quad regimen achieves high rate of virologic suppression

1 reference

12 December 2020

Development of antiretroviral drug resistance

1 reference

12 December 2020

6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors

1 reference

12 December 2020

Anti-infectives: clinical progress of HIV-1 integrase inhibitors

1 reference

12 December 2020

Update of the drug resistance mutations in HIV-1: December 2010.

1 reference

12 December 2020

Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.

1 reference

12 December 2020